Icandra

Metformin Hydrochloride and Vildagliptin, the active ingredients in Icandra, are oral antidiabetic agents presented as a fixed‑dose combination tablet for oral use. They are employed to improve blood glucose control in adults with type 2 diabetes mellitus. The combination leverages complementary mechanisms to reduce hepatic glucose production and enhance insulin secretion, providing a convenient option for patients who need dual therapy.

GNH USA supplies Icandra as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality and regulatory conformity.

Icandra is indicated for the management of type 2 diabetes mellitus, targeting hyperglycemia through combined oral therapy.

- Type 2 diabetes mellitus: improves overall glycemic control when added to diet and exercise. - Inadequate response to metformin alone: provides additional glucose‑lowering effect. - Combination therapy: reduces the need for multiple separate tablets, simplifying regimen.

The combination of metformin and vildagliptin may be associated with several adverse reactions, ranging from mild to serious.

Common Side Effects: - Gastrointestinal upset: nausea, abdominal discomfort, or diarrhea. - Headache: mild to moderate intensity. - Dizziness: transient episodes, especially on initiation.

Serious or Rare Side Effects: - Lactic acidosis: rare but potentially fatal metabolic complication. - Severe hypoglycemia: especially when combined with other glucose‑lowering agents. - Pancreatitis: acute inflammation of the pancreas presenting with abdominal pain. - Hepatic dysfunction: elevated liver enzymes or hepatitis. - Allergic reactions: rash, pruritus, or angioedema.

Before prescribing Icandra, clinicians should evaluate patient-specific factors and monitor for potential risks. - Renal function: assess creatinine clearance and avoid use in severe renal impairment. - Hepatic function: monitor liver enzymes, contraindicated in significant hepatic disease. - Lactic acidosis risk: discontinue if signs of metabolic acidosis appear. - Pregnancy and lactation: safety not established; use only if benefits outweigh risks. - Drug interactions: review concomitant medications that may affect glucose or renal status. - Store at room temperature: keep in original container, protect from moisture and heat.

Icandra can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Contrast media: may precipitate renal dysfunction and increase lactic acidosis risk. - Alcohol abuse: enhances risk of lactic acidosis when combined with metformin.

Moderate Interactions (Monitor Closely): - Sulfonylureas or insulin: may increase hypoglycemia; dose adjustment may be required. - Diuretics: can reduce renal clearance of metformin, necessitating monitoring. - NSAIDs: may impair renal function, affecting metformin elimination.